Concerns that US tariffs on Australian pharmaceuticals could deliver a major blow to the economy appear overstated, according to the International Monetary Fund’s latest assessment of Australia’s outlook, which instead points to rising and mostly unavoidable health spending as the far more significant long-term policy challenge.
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Older Australians given three weeks to have their say on in-home aged care services list
November 3, 2026 - - Latest News -
Diabetes scheme registrations fall as health department points to GLP-1 use
November 3, 2026 - - Latest News -
Report finds 196 missing medicines and billions in unreinvested PBS savings
November 3, 2026 - - Latest News -
Medicines industry faces tough PBS talks, but will it be the most challenging ever?
November 3, 2026 - - Latest News -
Australians with thyroid eye disease gain first PBS subsidised treatment
November 2, 2026 - - Latest News -
‘We are now bridled only by our imagination’. Amgen’s Paul Burton on AI and medicine’s hinge moment
November 2, 2026 - - Latest News -
Edwards Lifesciences opens new Sydney head office as heart valve disease burden grows
November 1, 2026 - - Latest News
